Sensus Healthcare (NASDAQ:SRTS) Share Price Crosses Below 50 Day Moving Average of $3.72

Sensus Healthcare, Inc. (NASDAQ:SRTS)’s stock price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.72 and traded as low as $3.53. Sensus Healthcare shares last traded at $3.61, with a volume of 72,070 shares traded.

Sensus Healthcare Stock Down 4.0 %

The firm has a market capitalization of $59.17 million, a P/E ratio of 120.37 and a beta of 0.92. The firm has a 50 day moving average of $3.72 and a 200-day moving average of $3.07.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.14. The business had revenue of $12.57 million during the quarter, compared to analysts’ expectations of $12.10 million. Sensus Healthcare had a return on equity of 1.04% and a net margin of 1.99%. As a group, research analysts expect that Sensus Healthcare, Inc. will post 0.08 EPS for the current year.

Institutional Investors Weigh In On Sensus Healthcare

Several institutional investors have recently made changes to their positions in the stock. Perritt Capital Management Inc. boosted its stake in shares of Sensus Healthcare by 5.0% in the third quarter. Perritt Capital Management Inc. now owns 105,586 shares of the company’s stock valued at $292,000 after buying an additional 5,000 shares during the period. Sachetta LLC bought a new stake in shares of Sensus Healthcare in the fourth quarter valued at approximately $247,000. Finally, Creekmur Asset Management LLC bought a new stake in shares of Sensus Healthcare in the fourth quarter valued at approximately $83,000. 25.30% of the stock is currently owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.